Smad2 and smad3 are redundantly essential for the suppression of inos synthesis in macrophages by regulating IRF3 and STAT1 pathways

International Immunology

Volumn 24, Issue 4, 2012, Pages 253-265

  Sugiyama, Yuki ^a,b   Kakoi, Kyosuke ^a,b   Kimura, Akihiro ^a,b   Takada, Ichiro ^a,b   Kashiwagi, Ikko ^a,b   Wakabayashi, Yu ^a,b   Morita, Rimpei ^a,b   Nomura, Masatoshi ^c   Yoshimura, Akihiko ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Immunosuppression; Signal transduction; TGF ; TLR

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 6; NITRIC OXIDE; SMAD2 PROTEIN; SMAD3 PROTEIN; STAT1 PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED MACROPHAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INDUCTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 84859207428     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr126     Document Type: Article

References (42)

1. Fortunel, N. O., Hatzfeld, A. and Hatzfeld, J. A. 2000. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96:2022.
2. Massague, J., Blain, S. W. and Lo, R. S. 2000. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295.
3. Vodovotz, Y., Geiser, A. G., Chesler, L. et al. 1996. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. J. Exp. Med. 183:2337.
4. McCartney-Francis, N. L. and Wahl, S. M. 2002. Dysregulation of IFN-gamma signaling pathways in the absence of TGF-beta 1. J. Immunol. 169:5941.
5. Ding, A., Nathan, C. F., Graycar, J., Derynck, R., Stuehr, D. J. and Srimal, S. 1990. Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J. Immunol. 145:940.
6. Nelson, B. J., Ralph, P., Green, S. J. and Nacy, C. A. 1991. Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J. Immunol. 146:1849.
7. Vodovotz, Y., Bogdan, C., Paik, J., Xie, Q. W. and Nathan, C. 1993. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178:605.
8. Mitani, T., Terashima, M., Yoshimura, H., Nariai, Y. and Tanigawa, Y. 2005. TGF-beta1 enhances degradation of IFN-gamma-induced iNOS protein via proteasomes in RAW 264.7 cells. Nitric Oxide 13:78.
9. Takimoto, T., Wakabayashi, Y., Sekiya, T. et al. 2010. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J. Immunol. 185:842.
10. Werner, F., Jain, M. K., Feinberg, M. W. et al. 2000. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J. Biol. Chem. 275:36653.
11. Yasukawa, H., Ohishi, M., Mori, H. et al. 2003. IL-6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4:551.
12. Matsumura, Y., Kobayashi, T., Ichiyama, K. et al. 2007. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J. Immunol. 179:2170.
13. Flanders, K. C., Sullivan, C. D., Fujii, M. et al. 2002. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am. J. Pathol. 160:1057.
14. Hiwatashi, K., Tamiya, T., Hasegawa, E. et al. 2011. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Lett. 308:172.
15. Takaesu, G., Kishida, S., Hiyama, A. et al. 2000. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 5:649.
16. Yoshida, R., Takaesu, G., Yoshida, H. et al. 2008. TRAF6 and MEKK1 play a pivotal role in the RIG-I-like helicase antiviral pathway. J. Biol. Chem. 283:36211.
17. Takaki, H., Minoda, Y., Koga, K., Takaesu, G., Yoshimura, A. and Kobayashi, T. 2006. TGF-beta1 suppresses IFN-gamma-induced NO production in macrophages by suppressing STAT1 activation and accelerating iNOS protein degradation. Genes Cells 11:871.
18. Sironi, J. J. and Ouchi, T. 2004. STAT1-induced Apoptosis Is Mediated by Caspases. 2, 3, and 7. J. Biol. Chem. 279:4066.
19. Koga, K., Takaesu, G., Yoshida, R. et al. 2009. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 30:372.
20. Hashimoto, M., Ayada, T., Kinjyo, I. et al. 2009. Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. Cancer Sci. 100:730.
21. Cui, S., Reichner, J. S., Mateo, R. B. and Albina, J. E. 1994. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res. 54:2462.
22. Fariaseisner, R., Sherman, M. P., Aeberhard, E. and Chaudhuri, G. 1994. Nitric-oxide is an important mediator for tumoricidal activity in-vivo. Proc. Natl Acad. Sci. USA 91:9407.
23. Lewis, R. S., Kolesnik, T. B., Kuang, Z. et al. 2011. TLR regulation of SPSB1 controls inducible nitric oxide synthase induction. J. Immunol. 187:3798.
24. Matsumoto, K., Nishiya, T., Maekawa, S. et al. 2011. The ECS(SPSB) E3 ubiquitin ligase is the master regulator of the lifetime of inducible nitric-oxide synthase. Biochem. Bioph. Res. Commun. 409:46.
25. Wakabayashi, Y., Tamiya, T., Takada, I. et al. 2011. H3K9 methyltransferase recruitment to the IL-2 promoter is a mechanism of suppression of IL-2 transcription by the TGF-b-Smad pathway. J. Biol. Chem. 286:35456.
26. Honda, K., Takaoka, A. and Taniguchi, T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349.
27. Theofilopoulos, A. N., Baccala, R., Beutler, B. and Kono, D. H. 2005. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23:307.
28. Kawai, T., Takahashi, K., Sato, S. et al. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6:981.
29. Kawai, T. and Akira, S. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131.
30. Takahasi, K., Suzuki, N. N., Horiuchi, M. et al. 2003. X-ray crystal structure of IRF-3 and its functional implications. Nat. Struct. Biol. 10:922.
31. Qin, B. Y., Liu, C., Lam, S. S. et al. 2003. Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat. Struct. Biol. 10:913.
32. Reardon, C. and McKay, D. M. 2007. TGF-beta suppresses IFNgamma-STAT1-dependent gene transcription by enhancing STAT1-PIAS1 interactions in epithelia but not monocytes/macrophages. J. Immunol. 178:4284.
33. Alvarez Mde, L., Quiroga, A. D., Parody, J. P. et al. 2009. Crosstalk between IFN-alpha and TGF-beta1 signaling pathways in preneoplastic rat liver. Growth Factors 27:1.
34. Nandan, D. and Reiner, N. E. 1997. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J. Immunol. 158:1095.
35. Dong, Y., Tang, L., Letterio, J. J. and Benveniste, E. N. 2001. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression. J. Immunol. 167:311.
36. Park, I. K., Shultz, L. D., Letterio, J. J. and Gorham, J. D. 2005. TGFbeta1 inhibits T-bet induction by IFN-gamma in murine CD4+ Tcells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J. Immunol. 175:5666.
37. Larsson, J., Blank, U., Helgadottir, H. et al. 2003. TGF-beta signaling-deficient hematopoietic stem cells have normal selfrenewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood 102:3129.
38. Larsson, J. and Karlsson, S. 2005. The role of Smad signaling in hematopoiesis. Oncogene 24:5676.
39. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23.
40. Sica, A. and Bronte, V. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117:1155.
41. Balkwill, F., Charles, K. A. and Mantovani, A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211.
42. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A. and Locati, M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677.